Vol.27/No.7

In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.

D. Ross Camidge, MD, PhD, reflects on his journey, from a gap year working at McDonald’s to directing the lung cancer program where he is now a patient.

HER3-DXd is being evaluated in the ongoing phase 3 HERTHENA-Breast04 trial in locally advanced or metastatic HR-positive, HER2-negative breast cancer.

Maurie Markman, MD, discusses the clinical utility of HPV vaccination as a strategy to prevent malignant disease.

Leah Wells, MD, breaks down the expansion and continued investigation of ADCs in lung cancer management.

Nicholas Zorko, MD, PhD, discusses B7-H3 targeting in lung, GU, and gynecologic malignancies.

Rising rates of early-onset cancers have prompted shifts in management strategies and new research avenues.

Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.

Gerald Soff, MD, discusses how romiplostim could improve long-term outcomes in patients with GI cancer and thrombocytopenia by preserving relative dose intensity.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.